On Good Friday, it became known that the US pharmaceutical industry had filed an application with the European Medicines Agency to approve the distribution of the Pfizer vaccine for children 12-15 years old, Reuters reported.
This was announced by Albert Burla, CEO of Pfizer. At the moment, the drug is approved for use in the European Union for the age group over 16 years old. However, after clinical trials, for which 2250 volunteers were involved, experts concluded that the vaccine is effective and safe for children aged 12-15 years.
In his message, the scientist, originally from Thessaloniki, noted:
“We share the urgent need to expand Pfizer and BioNTech vaccines to reach younger citizens. Today we are proud to have applied to Coreper for a license renewal for teens 12-15 years old. ”
According to Rossel Wallenski, director of the US Centers for Disease Control and Prevention at ABC, Pfizer and BioNTech have filed applications with US authorities as well. The vaccine license for adolescents 12-15 years old is expected in mid-May.
The head of BioNTech Ugur Sakhin reports that the results of clinical trials of vaccination for children aged 5 to 12 will be announced in July, and in September – for the younger age group from 6 months to 5 years.